Quick search:
Content Search
Result Content Research
Result Content Research
1 Fulcrum's FTX-6058 Shows Promise as SCD Therapy in Disease Models
2 Fulcrum Therapeutics Presents Published Structure of
3 Phase 1 Trial of Oral FTX-6058 to Promote Fetal Hemoglobin Set to Open
4 Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
5 The Development and Treatment Potential of FTX-6058
6 Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
7 Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual
8 Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease
9 Fulcrum Therapeutics Presents Updated Data on Sickle Cell
10 Sickle cell disease: Investigating a new drug
11 Virtual meeting delivers first time drug structures
12 Fulcrum Therapeutics Announces US Food and Drug Administration Grants Fast Track Designation to Losmapimod for the
13 Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer
14 Other news to note for April 12, 2021 | 2021-04-12
15 Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
16 Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
17 Study Identifies FDA-approved Medications With Potential to Treat SCD
18 Fulcrum Therapeutics to Evaluate Losmapimod as Potential
19 Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
20 The Recovery Room: News beyond the pandemic — April 16
21 Clinical Catch-Up: October 5-9
22 Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 PatientsFulcrum receives early notification from US Food and Drug Administration (FDA) that study may proceed
23 Fulcrum Therapeutics Inc (FULC) gains 0.4640% for June 14
24 Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
25 Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society
26 Novartis wins early FDA approval of P-selectin binder Adakveo in SCD
27 Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement
28 Fulcrum Therapeutics to Host Second Quarter 2020 Financial
29 $FULC Fulcrum Therapeutics Reports Q3 Loss Per Share $0.70
30 MyoKardia and Fulcrum Therapeutics Announce Multi-Target
31 Fulcrum Therapeutics (FULC) Up 65% In A Month, IPO Lockup Expires On Jan.14
32 The Second Wave Pandemic Portfolio (LAKE, APT, ALST, FLGT)
33 Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy
34 Top Sandwiches In South Florida – CBS Miami
35 Faker's top 5 plays from the Worlds 2019 group stage
36 Bridges of Pittsburgh: The Ohio River | Pittsburgh Post-Gazette